Characterization and differential retention of Q beta bacteriophage virus-like particles using cyclical electrical field–flow fractionation and asymmetrical flow field–flow fractionation

Shiri, Farhad; Petersen, Kevin E.; Romanov, Valentin; Zou, Qin; Gale, Bruce K.

doi:10.1007/s00216-019-02383-z

Cited by 18 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently it was shown that virus capsid, envelope and, sometimes, core viral proteins can form VLP structures. VLPs can be experimentally generated in the laboratory using recombinant viral proteins that are expressed in a range of expression systems including prokaryotic cells [6], yeast [7], insect cell lines [8,9], plants [10] and mammalian cell lines [11,12]. While VLPs are commonly produced using proteins(s) from a single virus type, chimeric VLPs can also be created by the assembly of structural proteins from different viruses [6].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

et al. 2021

View full text Add to dashboard Cite

Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review.

show abstract

mentioning

confidence: 99%

“…Structural proteins from viruses, such as human immunodeficiency virus (HIV), adeno-associated virus, Hepatitis B virus (HBV), Hepatitis C virus (HCV) and bacteriophages have been used to produce VLPs [9][10][11]. These particles are of different sizes, with most ranging from 20-200 nm.…”

mentioning

confidence: 99%

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…182 VLP have been used as model analytes to demonstrate, develop and improve sizing and particle counting methods. 186,188−191 Model bacteriophage VLP with and without two conjugated peptides were used to demonstrate the use two types of field-flow fractionation: AF4 and the better performing cyclical electrical field-flow fractionation (CyEIFF) 190 using MALS detection but also TEM of fractions collected from CyEIFF analysis. For SEC it is possible to increase throughput by interlaced injection, i.e., inject the next sample immediately after the monomeric VLP peak as demonstrated with HPV VLP.…”

Section: Virus-like Particles (Vlp)mentioning

confidence: 99%

Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells

Roesch

Zölls²,

Stadler³

et al. 2022

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Particles in biopharmaceutical formulations remain a hot topic in drug product development. With new product classes emerging it is crucial to discriminate particulate active pharmaceutical ingredients from particulate impurities. Technical improvements, new analytical developments and emerging tools (e.g., machine learning tools) increase the amount of information generated for particles. For a proper interpretation and judgment of the generated data a thorough understanding of the measurement principle, suitable application fields and potential limitations and pitfalls is required. Our review provides a comprehensive overview of novel particle analysis techniques emerging in the last decade for particulate impurities in therapeutic protein formulations (protein-related, excipient-related and primary packaging material-related), as well as particulate biopharmaceutical formulations (virus particles, virus-like particles, lipid nanoparticles and cellbased medicinal products). In addition, we review the literature on applications, describe specific analytical approaches and illustrate advantages and drawbacks of currently available techniques for particulate biopharmaceutical formulations.

show abstract

“…VLPs are highly organized structures that are readily identifiable by immune system cells and molecules [143,144]. Experimentally, VLPs are made by utilizing viral proteins that are produced in various expression systems such as prokaryotic cells [145], yeast [146], insect cell lines [147,148], plants [149], and mammalian cell lines [143,150], as depicted in Figure 5B. Cloning of the viral structural genes and expression of viral proteins with self-assembling capacity in an appropriate expression platform are the first steps in the manufacturing process for VLP-based vaccines, as detailed above.…”

Section: Virus-like Particle (Vlp) Vaccinesmentioning

confidence: 99%

“…Usually, most VLPs are made from a single virus's protein(s), but chimeric VLPs can be made by combining structural proteins from distinct viruses [145]. VLPs have been created using structural proteins from viruses such as HIV, adeno-associated virus, Hepatitis B, C, and bacteriophages [148][149][150].…”

Section: Virus-like Particle (Vlp) Vaccinesmentioning

confidence: 99%

Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat COVID-19. In this context, using databases such as PubMed, Google Scholar, and Science Direct, we gathered information about nanotechnology’s involvement in the prevention, diagnosis and virus-like particle vaccine development. This review revealed that various nanomaterials like gold, polymeric, graphene and poly amino ester with carboxyl group coated magnetic nanoparticles have been explored for the fast detection of SARS-CoV-2. Personal protective equipment fabricated with nanoparticles, such as gloves, masks, clothes, surfactants, and Ag, TiO2 based disinfectants played an essential role in halting COVID-19 transmission. Nanoparticles are used not only in vaccine delivery, such as lipid nanoparticles mediated transport of mRNA-based Pfizer and Moderna vaccines, but also in the development of vaccine as the virus-like particles elicit an immune response. There are now 18 virus-like particle vaccines in pre-clinical development, with one of them, developed by Novavax, reported being in phase 3 trials. Due to the probability of upcoming COVID-19 waves, and the rise of new diseases, the future relevance of virus-like particles is imperative. Furthermore, psychosocial variables linked to vaccine reluctance constitute a critical problem that must be addressed immediately to avert pandemic.

show abstract

Characterization and differential retention of Q beta bacteriophage virus-like particles using cyclical electrical field–flow fractionation and asymmetrical flow field–flow fractionation

Cited by 18 publications

References 45 publications

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells

Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines

Contact Info

Product

Resources

About